Sublingual Formulation of Anticancer Compound for Use in the Treatment of Autoimmune Neurodegenerative Diseases

A method of treating multiple sclerosis (MS), myasthenia gravis (MG), or neuromyelitis optical spectrum disorders (NMOSD) comprising administering an effective amount of a transmucosal delivery composition in form of a sublingual orally dispersible film comprising cladribine as active ingredient and comprising at least two hydrophilic polymers, wherein the at least two hydrophilic polymers represent at least 20% (w/w), preferably at least 25% (w/w), of the total composition, wherein cladribine is contained in the composition as a cladribine-cyclodextrin complex, wherein the at least two hydrophilic polymers comprise at least one structure forming polymer and at least one binding and/or intercalating polymer, wherein the at least one structure forming polymer is selected from starch polymers and wherein the at least one binding and/or intercalating polymer is pullulan.